Clinical Trials Logo

Secondary Immunodeficiency clinical trials

View clinical trials related to Secondary Immunodeficiency.

Filter by:
  • None
  • Page 1

NCT ID: NCT03677557 Recruiting - Clinical trials for Primary Immunodeficiency Disease

Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

Start date: September 19, 2018
Phase: Phase 4
Study type: Interventional

Patients with primary or secondary immunodeficiency disease who have developed adverse reactions to products available on the market such as Cuvitru® (Shire), Hizentra® (CSL Behring) or 10% Gammunex® (Grifols), may benefit from utilizing 16.5% Cutaquig® (Octapharma).